These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 28687599)

  • 1. PSMA Ligands for PET Imaging of Prostate Cancer.
    Schwarzenboeck SM; Rauscher I; Bluemel C; Fendler WP; Rowe SP; Pomper MG; Afshar-Oromieh A; Herrmann K; Eiber M
    J Nucl Med; 2017 Oct; 58(10):1545-1552. PubMed ID: 28687599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
    Hofman MS; Hicks RJ; Maurer T; Eiber M
    Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
    Barrio M; Fendler WP; Czernin J; Herrmann K
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSMA PET and Radionuclide Therapy in Prostate Cancer.
    Bouchelouche K; Turkbey B; Choyke PL
    Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
    Hofman MS; Iravani A
    PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
    Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
    Ravi Kumar AS; Lawrentschuk N; Hofman MS
    Curr Opin Urol; 2020 Sep; 30(5):628-634. PubMed ID: 32701720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of standard and delayed imaging to improve the detection rate of [
    Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An
    Dietlein F; Hohberg M; Kobe C; Zlatopolskiy BD; Krapf P; Endepols H; Täger P; Hammes J; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
    J Nucl Med; 2020 Feb; 61(2):202-209. PubMed ID: 31324713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence.
    Ferdinandus J; Fendler WP; Hadaschik B; Herrmann K
    Curr Opin Urol; 2020 Sep; 30(5):635-640. PubMed ID: 32732621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
    Koschel S; Murphy DG; Hofman MS; Wong LM
    Curr Opin Urol; 2019 Nov; 29(6):569-577. PubMed ID: 31567440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
    Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
    Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer.
    Farolfi A; Calderoni L; Mattana F; Mei R; Telo S; Fanti S; Castellucci P
    J Nucl Med; 2021 May; 62(5):596-604. PubMed ID: 33712536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
    Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of
    Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
    Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Detection of Bilateral Testicular Metastases From Prostatic Adenocarcinoma Using 68Ga-PSMA Ligand PET/CT.
    Weiberg D; Radner H; Derlin T; Thon WF
    Clin Nucl Med; 2017 Jul; 42(7):563-564. PubMed ID: 28368893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence-A Narrative Review of the Literature.
    Ekmekcioglu Ö; Busstra M; Klass ND; Verzijlbergen F
    J Nucl Med; 2019 Oct; 60(10):1394-1398. PubMed ID: 30850500
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.